Filing Flows

Filing Flows › Fulgent Genetics (FLGT) › Next earnings date

Fulgent Genetics (FLGT) earnings: beat the estimate

Fulgent Genetics (FLGT) reported on Nov 5, 2026 and beat the EPS estimate: −$0.09 against −$0.65 (+86.2%). Revenue was $90.4M for Q3 2026, +8% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+86.2% vs estimate
Beat rate60%

The last report

Fulgent Genetics reported revenue of $90.4M for the third quarter 2026 (+8% Y/Y), net loss $13.3M. How it makes money → · Every quarter →

Fulgent Genetics: EPS against the estimate, last 5 reportsFulgent Genetics: EPS against the estimate, last 5 reportsEstimateReported−$0.22$0.14Nov 25$0.03$0.16Feb 26−$0.35−$0.36May 26−$0.44−$0.58Jul 26−$0.65−$0.09Nov 26
Latest (Nov 26): Estimate −$0.65, Reported −$0.09.

Fulgent Genetics' latest quarter

Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart follows the revenue to costs, profit and cash.

Questions

Did Fulgent Genetics beat earnings?

Fulgent Genetics (FLGT) reported on Nov 5, 2026 and beat the EPS estimate: −$0.09 against −$0.65 (+86.2%).

When does FLGT report earnings?

The next date is not set yet.

Does Fulgent Genetics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.